Pravastatin treatment before coronary artery bypass grafting for reduction of postoperative atrial fi brillation

General Thoracic and Cardiovascular Surgery

Volumn 58, Issue 3, 2010, Pages 120-125

  Tamura, Kiyoshi ^a,b   Arai, Hirokuni ^a   Ito, Fusahiko ^a   Someya, Takeshi ^a   Ushiyama, Tomohiro ^a   Miyagi, Naoto ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

Atrial fi brillation; C reactive protein; Coronary artery bypass grafting; Pravastatin; Statin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; MEVINOLIN; PIVASTATIN; PRAVASTATIN; SIMVASTATIN; STATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ONSET AGE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; RISK REDUCTION; THERAPY EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY BYPASS; DISEASE-FREE SURVIVAL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PRAVASTATIN; PROPORTIONAL HAZARDS MODELS; PYRROLES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950408331     PISSN: 18636705     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11748-009-0544-8     Document Type: Article

References (31)

1. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, et al. Predictors of atrial fi brillation after coronary artery surgery: current trends and impact on hospital resources. Circulation 1996;94:390-397
2. Yavuz T, Bertolet B, Bebool Y, Tunerir B, Aslan R, Ocal A, et al. Role of endogenous adenosin in atrial fi brillation after coronary artery bypass graft. Clin Cardiol 2004;1114:e257-354. (Pubitemid 38703088)
3. Gaunino M, Andreotti F, Zamparelli R, Di Castelnouvo A, Nasso G, Burzotta F, et al. The-174G/C interleukin-6 poly-
4. morphism infl uences postoperative interleukin-6 levels and post operative atrial fi brillation. Is atrial fi brillation an infl am-matory complication? Circulation 2003;108(suppl 1):II195-9.
5. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein in patients with atrial fi brillation. Circulation 2001;104:2886-2891
6. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenous JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fi brillation. Int J Cardiol 2006;115:135-143 (Pubitemid 46136515)
7. Creswell LL, Alexander JC Jr, Ferguson TB Jr, Lisbon A, Fleisher LA; American College of Chest Physicians. Intra-operative interventions: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fi brillation after cardiac surgery. Chest. 2005;128: 28-35. (Pubitemid 41134237)
8. Bradley D, Creswell LL, Hogue CW Jr, Epstein AE, Prys-towsky EN, Daoud EG,; American College of Chest Physicians. Intraoperative interventions: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fi brillation after cardiac surgery. Chest 2005;128:39-47. (Pubitemid 41134239)
9. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997;336:1429-1434
10. Maisel WH, Rawn JD, Stevenson WG. Atrial fi brillation after cardiac surgery. Ann Intern Med 2001;135:1061-1073
11. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL, et al. Statins and postoperative risk of atrial fi bril-lation following coronary artery bypass grafting. Am J Cardiol 2006;97:55-60. (Pubitemid 41828123)
12. Arnljot T, Morten G, Torstein G, Paul V, Anne GS, Even H, et al. Analysis of pravastatin to prevent recurrence of atrial fi brillation after electrical cardioversion. Am J Cardiol 2004; 93:780-782 (Pubitemid 38338579)
13. Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, Zhang L, et al. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 2007;71: 144-152 (Pubitemid 46045564)
14. Cox JL. A perspective of postoperative atrial fi brillation in cardiac operation. Ann Thorac Surg 1993;56:405.
15. Thompson AE, Hirsch GM, Pearson GJ. Assessment of new onset post coronary artery bypass surgery atrial fi brillation: current practice pattern review and the development of treatment guideline. J Clin Pharm Ther 2002;27:21-37.
16. Kumagai K, Nakashima H, Saku K. The HMG-CoA reduc-tase inhibitor atrovastatin prevents atrial fi brillation by inhibiting infl ammation in a canine sterile pericarditis model. Cardiovasc Res 2004;62:105-111 (Pubitemid 38326816)
17. Giuseppe P, Massimo C, Dario C, Vincenzo P, Andrea AD, Elvio C, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fi brillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (atrovastatin for reduction of myocardial dysrhythmia after cardiac surgery) study. Circulation 2006;114:1455-1461 (Pubitemid 44526999)
18. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Sinvastatin lowers C-reactive protein within 14days: an effective independent of fl ow-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-1452
19. BassoC, Corrado D, Rossi L, Thiene G. Ventricular preexi-tation in children and young adults: atrial myocarditis as a possible trigger of sudden death. Circulation. 2001;103: 269-275. (Pubitemid 32095414)
20. Fromer M, Genton C, Schlaepfer J, Goy JJ, Kappenberger L. Is there an isolated arrhythmogenic right atrial myocarditis? Eur Heart J 1990;11:566-571
21. Francisco M, Domingo AP, Vanessa R, Jose MA, Miguel A, Pedro LT, et al. Statins and postoperative risk of atrial fi bril-lation following coronary artery bypass grafting. Am J Cardiol 2006;97:55-60. (Pubitemid 41828123)
22. Mehmet O, Abdullah D, Ercan V, Sahin K, Nurullah T, Oktay P, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fi brillation. Cardiology 2007;107:117-121
23. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Grayboys T, Bilchik B, et al. Usefulness of statin drugs in protecting against atrial fi brillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379-1383
24. Siu CW, Lau CP, Tse HF. Prevention of atrial fi brillation recurrence by statin therapy in patients with lone atrial fi bril-lation after successful cardioversion. Am J Cardiol 2003;92: 1343-1345
25. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP, for the AVID investigators. Are lipid-lowering drugs also anti-arrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defi brillators (AVID) trial. J Am Coll Cardiol 2003;42:81-87
26. Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of pre-operative stain therapy and cardiac outcomes after coronary bypass grafting. Am J Cardiol 200;86:1128-1130
27. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl CoA reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-1935
28. Ridker PM, Rifai N, Pfeffer M, Sacks FM, Moye LA, Goldman S, et al. Infl ammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844
29. Michelle AA, Ellie D, Nader R, Paul MR, for the PRINCE investigators. Effect of statin therapy on C-reactive protein levels. JAMA 2001;286:64-70.
30. Ichihara K, Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 2002;359:2195-2198
31. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Usefulness of hydrophilic vs. lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI. Circ J 2007;71:1348-1353